Navigation Links
Kendle Revises Full Year 2008 Guidance
Date:1/12/2009

CINCINNATI, Jan. 12 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) a leading, global full-service clinical research organization, today announced revised financial expectations for the full year 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

The Company now expects full year 2008 net service revenues to be in the range of $475 million to $480 million, down from the previous range of $485 million to $500 million, primarily due to the strengthening U.S. dollar. Earnings per share for 2008 are expected to be in the range of $2.12 to $2.20 per diluted share compared to previous guidance of $2.10 to $2.25.

Amidst challenges across the industry resulting in a softening RFP flow, the Company expects to report a fourth quarter net book-to-bill ratio of approximately 1.3 to 1.

Kendle is scheduled to provide its next financial update for the fourth quarter and full year ended Dec. 31, 2008 on Feb. 25, 2009, at 8:30 a.m. (EST).

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. The company also has been recognized as "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and among the "Top CROs in Europe" in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com .

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements include, but are not limited to, sales, revenue and earnings expectations for the fourth quarter and entire year of 2008. Kendle cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained herein. Such factors include (a) continued fluctuation in the exchange rate of the U.S. dollar; (b) changes in the markets for the Company's service offerings; (c) changes in the market for customers' products; and (d) other risks as detailed from time to time in Kendle's SEC reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Annual Reports on Form 10-K.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
2. Kendle Appoints Ken Hintze, PhD, Vice President, Global Clinical Safety & Pharmacovigilance
3. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
4. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
5. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
6. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
7. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
8. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
9. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
10. Kendle to Present at 27th Annual J.P. Morgan Healthcare Conference
11. Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Doctors on Liens has ... by Dr. Kendell Mendonca , to its growing network of doctors in Central ... injuries stemming from car accidents such as whiplash, back pain, neck pain, hip and ...
(Date:2/21/2017)... Carrollton, Ga. (PRWEB) , ... February 21, 2017 , ... ... industry. To simplify the secure exchange of data across industry solutions, Fogo Data ... in the power of community. A healthy community is one in which all ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to ... backed by giants including Accenture, GE Ventures, and Software AG , will ...
(Date:2/21/2017)... ... February 21, 2017 , ... CLICKco LLC, a company dedicated ... are now available for purchase on RonnieColemanNutrition.com, a popular website for health and ... health-conscious consumers who love coffee but are looking to add more protein to ...
(Date:2/20/2017)... ... , ... Nancy Johnston Toll marks her debut in the publishing ... Bump in the Road ” (published by Xlibris). Inspired from her personal experiences, this ... ups and downs experienced by anyone going through cancer treatment and how one can ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... JOSE, Calif. , Feb. 21, 2017 Cadence ... that its Cadence ® Tensilica ® Fusion F1 ... ™ MAC IP offering. The licensable IP targets SoCs ... city and industrial applications. M2B leveraged the Fusion F1 DSP ... run value-added applications like voice trigger, audio identification and sensor ...
(Date:2/21/2017)... Research and Markets has announced the addition of the "Liver Cirrhosis ... ... Cirrhosis Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... answers the following questions: What are the key ... positioned in the Global Liver Cirrhosis market? What are ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Rosacea market? ...
Breaking Medicine Technology: